ClinicalTrials.gg
CompletedNCT02681198Updated Feb 23, 2018

Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers

A Phase 1 interventional study of Lofexidine and Paroxetine in Healthy, sponsored by USWM, LLC (dba US WorldMeds). Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-23.

Sponsored by USWM, LLC (dba US WorldMeds) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to determine the pharmacokinetics, safety and tolerability of lofexidine HCl in the presence of paroxetine in healthy adults.

Read the detailed description

This is a Phase 1, open-label, single-sequence study to determine the pharmacokinetics, safety and tolerability of lofexidine HCl in the presence of paroxetine in healthy adults. Lofexidine HCl is an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids. Paroxetine HCl is an orally administered psychotropic drug indicated in the treatment of major depressive, obsessive compulsive, panic, social anxiety, and generalized anxiety disorders. Paroxetine is a strong CYP2D6 inhibitor.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • Lofexidine
  • Paroxetine
  • Volunteer
03

In context

Lead sponsor

USWM, LLC (dba US WorldMeds) is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is between ages of 18 to 60 years at enrollment with a (BMI) between 18 and 35 kg/m2.
  • Female subjects must not be lactating, and must either a) be or b) agree to use an acceptable form of from screening until 14 days after completion of the study.
  • Subject is in good health based on medical history, physical exam, laboratory profile, and (ECG) as judged by the Investigator.
  • If subject smokes, subject agrees to limit smoking while in the study to not more than 10 cigarettes per day.

Exclusion criteria

Exclusion Criteria:

  • History of suicidal ideations or depression requiring professional intervention including counseling or antidepressant medication over the past 12 months.
  • History or presence of allergic or adverse response to lofexidine, paroxetine, or related drugs.
  • Received any drugs capable of inhibiting CYP enzymes CYP1A2, CYP2C19, or CYP2D6 within 14 days or 5 half-lives (whichever is more) before Day 1.
  • Consumes more than 7 drinks/week for women or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) or has a significant history of alcohol abuse or drug/chemical abuse within the last 1 year.
  • Has a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Lofexidine and paroxetine

    Lofexidine in the presence of paroxetine

    Drug: Lofexidine · Drug: Paroxetine

Interventions

  • All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.

  • All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: 0 hour (predose) and 0.25, 0.5, 1, 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48 and 72 hours after lofexidine Dose 1; 0 hour (predose) and 0.25, 0.5, 1 , 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48, 72, 96, 120, 144 and 168 hours after lofexidine Dose 2.

  2. Time to Maximum Plasma Concentration (Tmax)

    Time frame: 0 hour (predose) and 0.25, 0.5, 1, 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48 and 72 hours after lofexidine Dose 1; 0 hour (predose) and 0.25, 0.5, 1 , 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48, 72, 96, 120, 144 and 168 hours after lofexidine Dose 2.

  3. Apparent Terminal Elimination Half-life (T½)

    Time frame: 0 hour (predose) and 0.25, 0.5, 1, 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48 and 72 hours after lofexidine Dose 1; 0 hour (predose) and 0.25, 0.5, 1 , 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48, 72, 96, 120, 144 and 168 hours after lofexidine Dose 2.

  4. Area Under the Concentration-Time Curve from Time Zero to Last Quantified Concentration (AUC 0-t)

    Time frame: 0 hour (predose) and 0.25, 0.5, 1, 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48 and 72 hours after lofexidine Dose 1; 0 hour (predose) and 0.25, 0.5, 1 , 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48, 72, 96, 120, 144 and 168 hours after lofexidine Dose 2.

  5. Area Under the Curve from Time Zero to Infinity (AUC 0-infinity)

    Time frame: 0 hour (predose) and 0.25, 0.5, 1, 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48 and 72 hours after lofexidine Dose 1; 0 hour (predose) and 0.25, 0.5, 1 , 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48, 72, 96, 120, 144 and 168 hours after lofexidine Dose 2.

  6. Apparent Clearance (CL/F)

    Time frame: 0 hour (predose) and 0.25, 0.5, 1, 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48 and 72 hours after lofexidine Dose 1; 0 hour (predose) and 0.25, 0.5, 1 , 2, 3, 4, 5, 6.5, 8, 12, 16, 24, 32, 48, 72, 96, 120, 144 and 168 hours after lofexidine Dose 2.

Secondary outcomes

  1. Blood pressure (sitting and standing)

    Time frame: screening; predose and 3.5 and 7.5 hours postdose on Days 1, 13; Day 22.

  2. Heart rate (sitting and standing)

    Time frame: screening; predose and 3.5 and 7.5 hours postdose on Days 1 and 13; Day 22.

  3. Laboratory Assessments

    Measurements in hematology, blood chemistry, coagulation, and urinalysis parameters will be examined. Labs will be done at screening, and at Days -1, 2,12,14, 22.

    Time frame: screening; Day -1, 2, 12, 14; Day 22.

  4. 12-lead ECGs

    Time frame: screening; 0 and 6.5 hours postdose on Days 1, 12, 13; Day 22.

  5. Holter ECGs

    Time frame: 0 (predose), and 3, 4 and 8 hours postdose on Days 1, 12, 13

  6. Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: screening; Days 7, 13, 22, 50.

07

Study locations

1 site
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2016
First posted
Feb 12, 2016
Start
Jan 2016
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Feb 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02681198
Lead sponsor
USWM, LLC (dba US WorldMeds)
Responsible party
Sponsor
First posted
Feb 12, 2016
Start date
Jan 2016
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Feb 23, 2018

Study contacts

George J Atiee, MD
principal investigator · Worldwide Clinical Trials

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lofexidine · Paroxetine

Start the discussion